Join Xcenda's Global HEOR consultants in Glasgow, Scotland as they demonstrate their global perspective, as well as findings from the latest evidence-based research at ISPOR's 20th Annual European Congress from 5-8 November 2017.  Meet us at booth #602.

SCIENTIFIC PRESENTATIONS

Symposium

PRACTICAL IMPLICATIONS OF VALUE-BASED PRICING AND EMERGING VALUE FRAMEWORKS IN HEALTH TECHNOLOGY ASSESSMENT
Tuesday, 7 November 2017 |12:30- 13:30

In light of growing competition for innovative therapies in addition to rising cost of treatments, manufacturers are pressured to demonstrate product value both clinically and economically. One leading payment model that has led such efforts to align with this objective is value-based pricing (VBP), in which financial risk is shared between manufacturers and payers. VBP has emerged as a front-runner in addressing product value by associating product prices with actual patient health outcomes.

However, efforts to implement the model have been limited and proven challenging. Organizations have also taken various approaches to defining drug value, including the American Society of Clinical Oncology (ASCO) Value Framework, the European Society of Medical Oncology (ESMO) Magnitude of Clinical Benefit Scale, the Institute for Clinical and Economic Review (ICER) Evidence Reports, and the Memorial Sloan Kettering Cancer Center (MSKCC) Drug Abacus. ASCO, ESMO, and MSKCC tools have focused on the rising cost of oncology therapies, whereas the ICER reports span across multiple therapeutic areas. Due to varying methodologies in these approaches and the limited, proprietary nature of current VBP agreements, the durability of VBP remains to be determined. We will discuss the practical implications of VBP, expand on the highlights and shortcomings of these value frameworks, and explore the implications for stakeholders.

  • Moderator: Jay Jackson, PharmD, MPH
    Senior Vice President, Consulting Services, Xcenda, Palm Harbor, FL, USA
  • Speaker: Andrew Briggs, DPhil, MSc
    Visiting Investigator, Center for Health Policy and Outcomes, Department of Epidemiology & Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, NY, USA
  • Speaker: Ansgar Hebborn, PhD
    Head Global Market Access Policy, Global Pricing & Market Access (GPMA), F.Hoffmann-La-Roche AG, Basel, Switzerland
  • Speaker: Ken O'Day, PhD, MPA
    Director, Global Health Economics, Xcenda, Palm Harbor, FL, USA

Issue Panel

Monday, 6 November 2017 | 15:45 - 16:45

Number Title Participants
7483 ARE EXISTING HEALTH TECHNOLOGY ASSESSMENT REQUIREMENTS INADEQUATE FOR ESTABLISHING VALUE FOR POTENTIALLY TRANSFORMATIVE GENE THERAPIES?

Moderator: Kellie Meyer
Panelists:

  • Ron Akehurst, DSc, Chairman, BresMed Health Solutions and Emeritus Professor of Health Economics at University of Sheffield School of Health and Related Research (ScHARR)
  • Clark Paramore, Head of Value Demonstration, bluebird bio
  • Adrian Towse, MPhil, Director, Office of Health Economics

 

Podium Presentation

Monday, 6 November 2017 | 14:15 - 15:15

Number Title Xcenda Co-author(s)
HT2 HEALTH TECHNOLOGY ASSESSMENT DECISIONS IN IMMUNO-ONCOLOGY THERAPIES: RESULTS, RATIONALES, AND TRENDS Chelsey Campbell, Victor Nguyen, Ryan Clark, Kellie Meyer

 

Poster Presentations

Poster Presentations Session I: Monday, 6 November 2017
Poster Display Hours: 8:45 - 14:15 | Poster Author Discussion: 13:15 - 14:15

Poster Number Title Xcenda Co-author(s)

PCN230

QUALITY OF LIFE (QoL), FUNCTIONAL STATUS (FS), AND SURVIVAL IN TRIPLE NEGATIVE BREAST CANCER (TNBC): DISCORDANCE OF DEFINITIONS BETWEEN A TARGETED LITERATURE REVIEW AND STAKEHOLDER INTERVIEWS Vishwas Agashe, Amy M. Duhig, Jennifer Floyd, Brett Maiese, Samantha Slaff
PCN244 APPLICATION STUDY OF THE EQ-5D-5L IN ONCOLOGY: LINKING SELF-REPORTED QUALITY OF LIFE OF PATIENTS WITH METASTATIC COLORECTAL CANCER TO CLINICAL DATA FROM A GERMAN TUMOR REGISTRY Kathrin Borchert, Christian Jacob, Dominik Meise, Julia Altevers, Thomas Mittendorf , Sabastian Braun
PCN276 GERMAN AMNOG BENEFIT ASSESSMENT: THE TYPE OF APPROPRIATE COMPARATOR MAKES THE DIFFERENCE Corinna Templin, Sandra Billig, Daniela Damen D, Werner Kulp
PCN90 ASSESSING THE HEALTHCARE COST OF DIABETIC NON-SMALL CELL LUNG CANCER PATIENTS COMPARED TO NON-SMALL CELL LUNG CANCER PATIENTS Cynthiya Ruban
PCN30 CLINICAL COMPARISON OF FIRST-LINE PLATIN CHEMOTHERAPY REGIMENS IN PATIENTS WITH ADVANCED NONSQUAMOUS NON-SMALL CELL LUNG CANCER (NSCLC) USING GERMAN REGISTRY DATA Jennifer Haas, Dominik Meise, Augustina Ogbonnaya, Sebastian Braun, Michael Eaddy
PCN320 RELEVANCE OF REAL WORLD DATA IN GERMAN AMNOG SUBMISSIONS IN ONCOLOGY Jennifer Haas, Kathrin Borchert,  Jan-Frederik Löpmeier, Sebastian Braun, Thomas Mittendorf
PCN325 TRENDS IN ONCOLOGY APPRAISAL DECISIONS: A COMPARISON BETWEEN THE NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE (NICE) AND THE SCOTTISH MEDICINES CONSORTIUM (SMC) Dave Campbel, Ryan Clark, Kellie Meyer
PCN74 THE ECONOMIC IMPACT OF SWITCHING TO HERCEPTIN (TRASTUZUMAB) BIOSIMILAR FOR THE TREATMENT OF METASTATIC BREAST CANCER FROM A UK PAYER PERSPECTIVE Duncan Brown, Duygu Bozkaya
PCN90 ASSESSING THE HEALTHCARE COST OF DIABETIC NON-SMALL CELL LUNG CANCER PATIENTS COMPARED TO NON-SMALL CELL LUNG CANCER PATIENTS  Cynthiya Ruban

 

Poster Presentations Session II: Monday, 6 November 2017
Poster Display Hours: 15:45 - 19:30 | Poster Author Discussion: 18:30 - 19:30

Poster Number Title Xcenda Co-author(s)
PHS106 ASSESSING THE UTILIZATION OF DIABETIC NON-SMALL CELL LUNG CANCER PATIENTS COMPARED TO NON-SMALL CELL LUNG CANCER PATIENTS Cynthiya Ruban
PHS3 INVESTIGATION OF DEMOGRAPHIC DIFFERENCES FOR NON-SMALL CELL LUNG CANCER PATIENTS WITH AND WITHOUT TYPE 2 DIABETES Cynthiya Ruban
PSY119 TRANSITION FROM ORPHAN DISEASE TO FULL ASSESSMENT IN THE GERMAN AMNOG SYSTEM: KEY LEARNINGS FROM PIONEERS Corinna Templin, Kim Erwes, Nadia Italia, Werner Kulp

 

Poster Presentations Session III: Tuesday, 7 November 2017
Poster Display Hours: 8:45 - 13:30 | Poster Author Discussion: 12:30 - 13:30

Poster Number Title Xcenda Co-author(s)
PCV34 SURVIVAL DIFFERENCES IN HEART FAILURE PATIENTS WITH AND WITHOUT IRON DEFICIENCY OR ANEMIA AND BY IRON TREATMENT Julia Altevers, Christian Jacob, Christopher Maas, Kim Krinke, Sebastian Braun
PMD131 COST AND OPERATIONAL EFFICIENCY COMPARISON OF AN INTEGRATED VS. A MULTI-STEP SYSTEM FOR EXTRACORPOREAL PHOTOPHERESIS IN GERMANY Christopher Maas, Ulrike Kuchenbecker
PMD53 REMOTE THERAPY MANAGEMENT OF PATIENTS ON AUTOMATED PERITONEAL DIALYSIS DEMONSTRATES COST SAVINGS IN GERMANY AND ITALY Kim McLeod

 

Poster Presentations Session IV: Tuesday, 1 November 2016
Poster Display Hours: 15:30 - 19:15 | Poster Author Discussion: 18:15 - 19:15

Poster Number Title Xcenda Co-author(s)
PHP11 RECENT TRENDS IN PROVIDER PERCEPTIONS AND USE OF VALUE FRAMEWORKS IN THE UNITED STATES (US) Duncan Brown, Chelsey Campbell, Kristen Migliaccio-Walle, Jay Jackson, Kellie Meyer
PHP148 NON-QUANTIFIABLE BENEFIT WITHIN THE GERMAN AMNOG SYSTEM: FACTORS CONTRIBUTING TO TIME LIMITS SET FOR BENEFIT RESOLUTIONS AND POTENTIAL IMPLICATIONS ON PRICE DISCOUNTS Ulrike Beckert, Hanne Vorwerk,
Jan-Frederik Löpmeier, Werner Kulp
PHP222 THE IMPACT OF PATIENT PREFERENCE STUDIES IN THE GERMAN HEALTHCARE SYSTEM Kim Krinke, Kathrin Borchert, Sebastian Braun, Thomas Mittendorf
PHP240 WHEN THE OUTCOME OF AN APPRAISAL IS NOT NICE: A REVIEW OF NICE APPEALS Ken O’Day, Dave Campbell, Kellie Meyer
PHP253 DO NICE APPEALS MAKE A DIFFERENCE? IMPACT OF APPEALS ON APPRAISAL OUTCOMES Ken O’Day, Dave Campbell, Kellie Meyer
PHP257 AMNOG DOSSIERS AS A CHALLENGE FOR PHARMACEUTICAL COMPANIES: IS THERE A CORRELATION BETWEEN VOLUMES AND ADDED MEDICAL BENEFIT? Werner Kulp,  Michael Reinartz
PHP258 UTILIZATION AND EVALUATION OF DELPHI PANELS IN GERMAN AMNOG ASSESSMENTS Kim Kohlscheen, Christian Jacob, Julia Altevers, Thomas Mittendorf
PHP263 A COMPARISON OF HEALTH TECHNOLOGY (HTA) REQUIREMENTS FOR SYSTEMATIC LITERATURE REVIEWS (SLRS) Evelyn Sarnes, Sarah Cadarette, Kimberly Gittings, Werner Kulp, Kimberly Ruiz, Erika Wissinger
PND70 2017 UPDATE OF RECENT TRENDS IN MULTIPLE SCLEROSIS-RELATED HEALTH TECHNOLOGY ASSESSMENT DECISIONS: AN ASSESSMENT OF FIVE COUNTRIES Ryan Clark, Chelsey Campbell, Kellie Meyer

 

Poster Presentations Session V: Wednesday, 8 November 2017
Poster Display Hours: 8:45 - 13:45 | Poster Author Discussion: 12:45 - 13:45

Poster Number Title Xcenda Co-author(s)

PRM225

APPLICATION OF BALANCING TECHNIQUES IN STUDIES UTILIZING GERMAN ADMINISTRATIVE CLAIMS DATA Dominic Meise,  Kim Kohlscheen,  Christian Jacob, Sebastian Braun
PRM231 APPLICATION OF MIXED-METHOD STUDY DESIGNS IN HEALTH- ECONOMIC- RELATED STUDIES. A NARRATIVE REVIEW. Ulrike Kuchenbecker,  Jacqueline Günther, Thomas Mittendorf
PRM251 ASSESSMENT OF ECONOMIC MODEL STABILITY BY REPEATED ONE-WAY SENSITIVITY ANALYSIS Lisa Bloudek, Ken O’Day
PRM81 OVERCOMING THE LIMITATIONS OF CLAIMS DATA: LINKAGE OF CLAIMS DATA WITH SECONDARY DATA SOURCES IN GERMANY Christian Jacob, Jacqueline Günther,
Kathrin Borchert, Kim Krinke,  Sebastian Braun

EVERY BRAND HAS CHALLENGES. XCENDA HAS ANSWERS. TALK TO US.

We're problem solvers. Through one point of contact, we'll connect your team with the collective insights and experience of our global health economists, pricing and reimbursement analysts, market access strategists, researchers, and -- most importantly -- experts who understand your world and what success demands.

Talk to us about your goals. We won't bore you with a sales pitch for our services. But you will get global insights and innovative strategies you hadn't thought of before.

Contact us to schedule a meeting in our client room at The Campanile Hotel, Glasgow.

PUBLICATION EXCELLENCE

Xcenda exhibits a strong publication track record across numerous therapeutic areas. Turn to Xcenda and benefit from a dedicated team of experienced professionals committed to excellence in HEOR. We can help you:

  • Understand evidentiary needs of global stakeholders
  • Develop a data-driven pharmacoeconomic strategy
  • Generate credible evidence
  • Create effective value demonstration tools
  • Extend the reach of your product value messages through scientific publications and posters